Examining the Efficacy of a Therapeutic Combination of Dronabinol (synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide for Obstructive Sleep Apnea

Trial Profile

Examining the Efficacy of a Therapeutic Combination of Dronabinol (synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide for Obstructive Sleep Apnea

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Dronabinol/palmitoylethanolamide (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Acronyms OSA Trial
  • Sponsors Therapix Biosciences
  • Most Recent Events

    • 09 Nov 2017 Status changed from planning to recruiting, according to a Therapix Biosciences media release.
    • 24 Oct 2017 New trial record
    • 18 Oct 2017 According to a Therapix Biosciences media release, this trial will be conducted under the leadership of Professor Yaron Dagan, head of the Sleep Medicine Institute at Assuta, and Principal Investigator, Dr. Lilach Kemer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top